利拉鲁肽联合二甲双胍治疗初诊肥胖2型糖尿病患者的临床疗效  

The analysis of the clinical effect of liraglutide combined with metformin on the treatment of initial diagnosis of type 2 diabetes with obesity

作　　者：司敏[1] 廖勇敢[1] 杨华[1] 

机构地区：[1]湖北医药学院附属人民医院,442000

出　　处：《中国老年保健医学》2017年第3期39-41,共3页Chinese Journal of Geriatric Care

摘　　要：目的探讨利拉鲁肽联合二甲双胍治疗初诊肥胖2型糖尿病患者的临床疗效。方法筛选我院内分泌科初诊肥胖2型糖尿病患者76例,随机分为对照组和观察组,对照组采用二甲双胍单药治疗,观察组采用利拉鲁肽联合二甲双胍治疗,记录两组患者治疗前后体重指数(BMI)、空腹血糖(FPG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS),用稳态模型评估胰岛素抵抗指数(HOMA-IR)及胰岛β细胞功能指数(HOMA-β),比较两组患者治疗前后上述指标的变化。结果治疗后两组患者BMI,FPG,2hPG,HBA1c,HOMA-IR,HOMA-β均明显改善,差异有统计学意义(P<0.05);观察组上述指标改善比对照组显著,差异具有统计学意义(P<0.05)。结论初诊肥胖2型糖尿病患者联合使用二甲双胍与利拉鲁肽疗效显著,有一定临床应用价值。Objectives To explore the clinical effect of liraglutide combined with mefformin on the initial diagnosed obesity type 2 diabetes. Methods In this study,76 obesity type 2 diabetes who were newly diagnosed in the Endocrinology Department were chose. They were divided into observation group and control group randomly. The observation group was supplied with liraglutide in combination with metformin,while the control group was provided with metformin only for treatment. Record the following information about each patien before and after treatment ： BMI （body mass index ）, FBG （fasting blood-glucose ）, 2hPBG （two hours postprandial blood glucose） ,glycohemoglobins（HbAlc） ,fasting insulin（FINS） ,Insulin resistance index（HOMA-IR） and islet beta function index （HOMA-β）were assessed by homeostasis model assessment. Comparisons were made between the index changes in each patient before and after the treatment. Results The BMI,FPG,2hPG,HbAlc,HOMA-β,HOMA-IR of observation group and control group obviously improved. All indexes of observation groups were remarkably superior to those of control group, thus making the contrast differences between groups meaningful instatistics （P 〈 0. 05）. Conclusion The clinical curative effect of liraglutide combined with mefformin in the treatment of the initially diagnosed obesity type 2 diabetes was significant, thus it has a certain clinical application value.

关 键 词：二甲双胍 利拉鲁肽 初诊 2型糖尿病 肥胖 

分 类 号：R587.1[医药卫生—内分泌]